Vemurafenib showed to inhibit the phosphorylation of the BRAF protein on immortalized cell lines of mutated ameloblastoma.16,19,30 Furthermore, it drastically reduced the symptoms and the tumor size, ensuring a good tolerance.61,62 The intraosseous neoplasm component seems to be less responsive to Dabrafenib than the extraosseous one, due to a primary neoplastic cell resistance.45 Therefore, in aggressive lesions, a combined therapy could be recommended. This evidence concerns the gene BRAF and ameloblastoma.